Browse by Tags

• Gilead: A drug habit worth having

  Posted Nov 06 2007, 04:53 AM by Jon Markman
  Filed under: Investing, Google, Microsoft, Apple, Trading
  Rating:

  

  When you think about the surprising success of the Nasdaq 100 index this year, the first things that naturally come to mind are tech powerhouses like Google, Apple and Microsoft. But you’ve got a leave a little room for the love of biotech too, and my favorite name there is Gilead Sciences.

  The immunology specialist has really proven immune to selling for most of its life in the public arena, as it is one of the most successful stocks of any type of the past 10 years, with 2,075% capital appreciation stemming from steadfast invention and marketing of biotech therapies.
  
  Pushing shares to a new high in the past week, though, were positive vibes at the 58th Annual Meeting of the American Society for the Study of Liver Disease currently taking place in Boston. Just in case you couldn’t attend, or haven’t checked out the abstracts, let me be the first to inform you that folks got pretty excited about a previously little-known compound being tested by Gilead with the exotic name GS-9190. It's a polymerase inhibitor therapy for hepatitis C that suddenly shows a lot of promise.   Read More...

  Discuss ( 2 comments) 60,264 Views Digg this | Email this | Link to this

• 'Halo' effect boosts Microsoft

  Posted Nov 02 2007, 02:06 AM by Jon Markman
  Filed under: Investing, Microsoft, Apple, Trading
  Rating:

  Even though this site is published by Microsoft, there's no reason we can't mention its stellar earnings report last week. I've been urging subscribers to my Strategic Advantage newsletter service to buy the stock since June in anticipation of a strong third and fourth quarter, and we have not been disappointed as fundamentals have improved dramatically and shares are up 25%.

  The key point: Mainstream investors of all stripes simply underestimated the impact of the new Xbox game Halo 3, rising PC sales in developing nations and the slow but steady purchase of the new Windows Vista operating system. Results were actually staggering, especially for an iconic firm which until recently seemed asleep at the wheel. Revenue soared 27% to nearly $14 billion, beating the consensus estimate by more than $1 billion. Earnings roared 23% higher, to $4.3 billion or 45 cents per share. For a company of this size, putting up growth in the 20%-plus range is no easy feat.   Read More...

  Discuss ( 5 comments) 23,543 Views Digg this | Email this | Link to this

• Leopard chases Apple shares higher

  Posted Oct 31 2007, 10:17 AM by Jon Markman
  Filed under: Investing, Apple, Trading
  Rating:

  Any doubts about the idea that Apple could produce another blow-out quarter this winter were put to rest this weekend when the company released its latest operating system, called Leopard. The company reports that it sold a staggering 2 million copies through its retail stores, resellers and online from Friday through Monday.
  
  Just to give you some perspective on that number: When Apple released its Jaguar operating system in 2002, it sold 100,000 in the first weekend. Two years ago, when it released the Tiger operating system, it took seven weeks to sell 2 million copies. So 2 million in three days has to blow you away. Regardless of the credit crunch, foreclosure crisis and rumors of consumer spending slowdown, Apple stores were packed this weekend.   Read More...

  Discuss ( 48 comments) 38,262 Views Digg this | Email this | Link to this